[go: up one dir, main page]

NO20061197L - Proteasominhibitorer og fremgangsmater for anvendelse av samme - Google Patents

Proteasominhibitorer og fremgangsmater for anvendelse av samme

Info

Publication number
NO20061197L
NO20061197L NO20061197A NO20061197A NO20061197L NO 20061197 L NO20061197 L NO 20061197L NO 20061197 A NO20061197 A NO 20061197A NO 20061197 A NO20061197 A NO 20061197A NO 20061197 L NO20061197 L NO 20061197L
Authority
NO
Norway
Prior art keywords
methods
same
proteasome inhibitors
compositions
boric acid
Prior art date
Application number
NO20061197A
Other languages
English (en)
Norwegian (no)
Inventor
Mohamed Iqbal
Sankar Chatterjee
Alberto Bernareggi
Paolo G Cassara
Edmondo Ferretti
Etnesto Menta
Patricia Messina Mclaughlin
Ambrogio Oliva
Arasmo Germano D
Sergio De Munari
Rafaella Bernardini
Original Assignee
Cephalon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34278521&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20061197(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cephalon Inc filed Critical Cephalon Inc
Publication of NO20061197L publication Critical patent/NO20061197L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • AIDS & HIV (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20061197A 2003-08-14 2006-03-14 Proteasominhibitorer og fremgangsmater for anvendelse av samme NO20061197L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US49576403P 2003-08-14 2003-08-14
US10/918,664 US7576206B2 (en) 2003-08-14 2004-08-12 Proteasome inhibitors and methods of using the same
PCT/US2004/026407 WO2005021558A2 (en) 2003-08-14 2004-08-13 Proteasome inhibitors and methods of using the same

Publications (1)

Publication Number Publication Date
NO20061197L true NO20061197L (no) 2006-05-11

Family

ID=34278521

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20061197A NO20061197L (no) 2003-08-14 2006-03-14 Proteasominhibitorer og fremgangsmater for anvendelse av samme
NO20150303A NO20150303L (no) 2003-08-14 2015-03-09 Proteasominhibitorer

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20150303A NO20150303L (no) 2003-08-14 2015-03-09 Proteasominhibitorer

Country Status (25)

Country Link
US (5) US7576206B2 (pl)
EP (1) EP1660507B2 (pl)
JP (1) JP4917431B2 (pl)
KR (1) KR101093880B1 (pl)
CN (1) CN102603781A (pl)
AT (1) ATE438650T2 (pl)
AU (1) AU2004268946B2 (pl)
BR (1) BRPI0413582B8 (pl)
CA (1) CA2535686C (pl)
CY (1) CY1109551T1 (pl)
DE (1) DE602004022424D1 (pl)
DK (1) DK1660507T4 (pl)
EA (1) EA010804B1 (pl)
ES (1) ES2330008T5 (pl)
HR (1) HRP20090590T4 (pl)
IL (2) IL173722A (pl)
IS (1) IS3013B (pl)
MX (1) MXPA06001687A (pl)
NO (2) NO20061197L (pl)
NZ (1) NZ545775A (pl)
PH (1) PH12012501372B1 (pl)
PL (1) PL1660507T5 (pl)
PT (1) PT1660507E (pl)
SI (1) SI1660507T1 (pl)
WO (1) WO2005021558A2 (pl)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7223745B2 (en) * 2003-08-14 2007-05-29 Cephalon, Inc. Proteasome inhibitors and methods of using the same
DE102005005397B4 (de) * 2005-02-05 2008-08-21 Lts Lohmann Therapie-Systeme Ag Isolierung von N-Butylbenzolsulfonamid, Synthese von Benzolsulfonamid-Derivaten sowie Verwendung von N-Butylbenzolsulfonamid und Benzolsulfonamid-Derivaten zur Behandlung der benignen Prostatahyperplasie und/oder des Prostatakarzinoms
US7468383B2 (en) * 2005-02-11 2008-12-23 Cephalon, Inc. Proteasome inhibitors and methods of using the same
KR20080030079A (ko) * 2005-07-05 2008-04-03 트러스티즈 오브 터프츠 칼리지 섬유아세포 활성 단백질 알파의 억제제
GEP20125599B (en) * 2007-08-06 2012-08-10 Millennium Pharm Inc Proteasome inhibitors
EA034601B1 (ru) * 2007-08-06 2020-02-25 Милленниум Фармасьютикалз, Инк. Способ получения бороновых кислот
US7442830B1 (en) * 2007-08-06 2008-10-28 Millenium Pharmaceuticals, Inc. Proteasome inhibitors
AU2016253697A1 (en) * 2007-08-06 2016-11-24 Millennium Pharmaceuticals, Inc. Proteasome inhibitors
WO2009026579A1 (en) * 2007-08-23 2009-02-26 Cornell Research Foundation, Inc. Proteasome inhibitors and their use in treating pathogen infection and cancer
US7838673B2 (en) * 2007-10-16 2010-11-23 Millennium Pharmaceuticals, Inc. Proteasome inhibitors
EP2088205A1 (en) 2008-02-11 2009-08-12 Institut National De La Sante Et De La Recherche Medicale (Inserm) PSMB10: A diagnosis marker and therapeutic target of chronic rejection.
BR122014008753A2 (pt) 2008-06-17 2015-12-29 Millennium Pharm Inc compostos de éster boronato e composições farmacêuticas dos mesmos
AR075090A1 (es) * 2008-09-29 2011-03-09 Millennium Pharm Inc Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden.
WO2010096574A1 (en) 2009-02-20 2010-08-26 Lisanti Michael P A method of diagnosis or prognosis of a neoplasm comprising determining the level of expression of a protein in stromal cells adjacent to the neoplasm
EP2238973A1 (en) 2009-04-07 2010-10-13 Cephalon France Lyophilized preparations of proteasome inhibitors
MX2011012538A (es) * 2009-05-27 2012-02-08 Cephalon Inc Terapia de combinacion para el tratamiento del mieloma multiple.
WO2010149688A2 (en) * 2009-06-24 2010-12-29 Pharma Mar, S.A. Antitumoral compounds
DK2769737T3 (en) 2009-07-20 2017-07-24 Bristol Myers Squibb Co COMBINATION OF ANTI-CTLA4 ANTIBODY WITH ETOPOSIDE FOR SYNERGISTIC TREATMENT OF PROLIFERATIVE DISEASES
BR112012009473A2 (pt) * 2009-10-22 2016-04-26 Polymedix Inc método para preparar um composto, e, composto
CN102725300B (zh) 2009-12-22 2015-03-11 赛福伦公司 蛋白酶体抑制剂及其制备、纯化、和应用的方法
CN102844313B (zh) * 2010-01-28 2016-10-05 哈佛大学校长及研究员协会 提高蛋白酶体活性的组合物和方法
CA2789400A1 (en) * 2010-02-09 2011-08-18 Ranbaxy Laboratories Limited Process for the preparation of bortezomib
JP2011184344A (ja) * 2010-03-08 2011-09-22 Kao Corp ｐ２１発現促進剤
CN106008570A (zh) 2010-03-31 2016-10-12 米伦纽姆医药公司 1-氨基-2-环丙基乙硼酸衍生物
CN102946879B (zh) 2010-04-19 2015-04-22 尼基制药公司 一种蛋白酶体抑制剂和镓络合物在制备治疗增殖性疾病的药物中的应用
TW201309303A (zh) 2011-03-03 2013-03-01 Cephalon Inc 用於治療狼瘡的蛋白酶體抑制劑
US9556166B2 (en) 2011-05-12 2017-01-31 Proteostasis Therapeutics, Inc. Proteostasis regulators
MX2013015308A (es) 2011-06-22 2014-05-20 Cephalon Inc Inhibidores de proteasoma y procesos para su preparacion, purificacion y uso.
UA115043C2 (uk) 2011-10-26 2017-09-11 Аллерган, Інк. Амідні похідні n-карбамідзаміщених амінокислот як модулятори формілпептидного рецептора 1 (fprl-1)
US20150184246A1 (en) 2011-11-11 2015-07-02 Millennium Pharmaceuticals, Inc. Biomarkers of response to proteasome inhibitors
JP6397765B2 (ja) 2011-11-11 2018-09-26 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． プロテアソーム阻害剤に応答するバイオマーカー
CA2862492A1 (en) 2012-01-24 2013-08-01 Millennium Pharmaceuticals, Inc. Methods of treatment of cancer
US10085987B2 (en) 2012-01-27 2018-10-02 Thomas Jefferson University MCT protein inhibitor-related prognostic and therapeutic methods
KR20140145203A (ko) * 2012-04-16 2014-12-22 알러간, 인코포레이티드 포르밀 펩타이드 수용체 2 조절물질로서 (2-우레이도아세트아미도)알킬 유도체
JP2013006855A (ja) * 2012-09-03 2013-01-10 Millennium Pharmaceuticals Inc プロテアソーム阻害剤
WO2014072985A1 (en) * 2012-11-06 2014-05-15 Natco Pharma Limited Novel boronic acid derivatives as anti cancer agents
WO2014116228A1 (en) 2013-01-25 2014-07-31 President And Fellows Of Harvard College Usp14 inhibitors for treating or preventing viral infections
CN105007909B (zh) 2013-03-06 2019-06-28 阿勒根公司 用于治疗眼部炎性疾病的甲酰基肽受体2激动剂的用途
RU2696487C2 (ru) 2013-03-06 2019-08-02 Аллерган, Инк. Применение агонистов формилпептидного рецептора 2 для лечения дерматологических заболеваний
MX368258B (es) 2013-03-15 2019-09-25 Zymeworks Inc Compuestos citotoxicos y antimitoticos y metodos de uso de los mismos.
EP2986290A4 (en) 2013-04-19 2017-01-04 Thomas Jefferson University Caveolin-1 related methods for treating glioblastoma with temozolomide
WO2015073528A1 (en) 2013-11-12 2015-05-21 Proteostasis Therapeutics, Inc. Proteasome activity enhancing compounds
RU2714933C2 (ru) 2013-12-27 2020-02-21 Займворкс Инк. Конъюгаты var2csa-лекарственное средство
CA2935077C (en) 2013-12-27 2022-03-15 Geoffrey C. Winters Sulfonamide-containing linkage systems for drug conjugates
US9493439B1 (en) 2014-04-07 2016-11-15 University Of Kentucky Research Foundation Proteasome inhibitors
CN106659761A (zh) 2014-05-20 2017-05-10 千年药物公司 初级癌症疗法后使用的含硼蛋白酶体抑制剂
KR102494557B1 (ko) 2014-09-17 2023-02-02 자임워크스 비씨 인코포레이티드 세포독성 및 항유사분열성 화합물, 그리고 이를 이용하는 방법
JP6662865B2 (ja) * 2014-10-01 2020-03-11 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ ボロン酸誘導体
MA41505A (fr) 2015-02-11 2017-12-19 Millennium Pharm Inc Nouvelle forme cristalline d'un inhibiteur de protéasome
US10577328B2 (en) 2015-07-23 2020-03-03 Taipei Medical University Aminonapthoquinone compounds and pharmaceutical composition for blocking ubiquitination-proteasome system in diseases
ES2825348T3 (es) 2015-07-30 2021-05-17 Calgent Biotechnology Co Ltd Compuestos y composición farmacéutica asociados al sistema ubiquitinación-proteasoma
CN106588965A (zh) * 2015-10-15 2017-04-26 北京大学 脲拟肽硼酸化合物及其药物组合物、制备方法和用途
CN105732683B (zh) * 2016-03-25 2018-10-16 南京林业大学 一类羧酸与α氨基酸组成的二肽硼酸及其酯类化合物、制备方法及其用途
CN106008572B (zh) * 2016-05-23 2018-08-17 成都千禧莱医药科技有限公司 一类二肽硼酸化合物及制备方法和用途
JP6223508B2 (ja) * 2016-06-27 2017-11-01 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． プロテアソーム阻害剤
SI3571208T1 (sl) * 2017-01-18 2021-06-30 Principia Biopharma Inc. Zaviralci imunoproteasomov
CN108440583B (zh) * 2017-01-23 2020-12-04 成都奥璟生物科技有限公司 一种新的硼酸衍生物及其药物组合物
US11667654B2 (en) * 2017-02-17 2023-06-06 Fresenius Kabi Oncology Ltd. Process for the preparation of boronic acid esters
WO2019053611A1 (en) 2017-09-14 2019-03-21 Glaxosmithkline Intellectual Property Development Limited POLY THERAPY FOR THE TREATMENT OF CANCER
JP2018024694A (ja) * 2017-10-03 2018-02-15 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． プロテアソーム阻害剤
LT3710457T (lt) * 2017-11-16 2022-11-10 Principia Biopharma Inc. Imunoproteasomos inhibitoriai
EA202090900A1 (ru) * 2017-11-16 2020-10-02 Принсипиа Биофарма Инк. Ингибиторы иммунопротеасом
US10537585B2 (en) 2017-12-18 2020-01-21 Dexcel Pharma Technologies Ltd. Compositions comprising dexamethasone
CN114075227B (zh) * 2020-08-19 2023-07-04 北京嵩润医药科技有限责任公司 吡唑硼酸类化合物、包含其的药物组合物及它们的用途
CN113105486B (zh) * 2021-02-24 2023-08-15 南京师范大学 一种硼酸酯类化合物及其药学上可接受的盐、其制备方法及其用途
US20250051367A1 (en) * 2021-12-06 2025-02-13 Pretzel Therapeutics, Inc. Heterocycle-containing lonp1 inhibitor compounds, uses and methods
WO2023220655A1 (en) 2022-05-11 2023-11-16 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
WO2023220641A2 (en) 2022-05-11 2023-11-16 Juno Therapeutics, Inc. Methods and uses related to t cell therapy and production of same
WO2024097905A1 (en) 2022-11-02 2024-05-10 Celgene Corporation Methods of treatment with t cell therapy and immunomodulatory agent maintenance therapy

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3301354A1 (de) 1983-01-18 1984-07-19 Matth. Hohner Ag, 7218 Trossingen Elektronisches musikinstrument
US4537773A (en) 1983-12-05 1985-08-27 E. I. Du Pont De Nemours And Company α-Aminoboronic acid derivatives
US4499082A (en) 1983-12-05 1985-02-12 E. I. Du Pont De Nemours And Company α-Aminoboronic acid peptides
JPS61233689A (ja) * 1985-03-22 1986-10-17 メルク・パテント・ゲゼルシヤフト・ミツト・ベシユレンクテル・ハフツング 複素環式ホウ素化合物
US5242904A (en) 1987-06-05 1993-09-07 The Dupont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
US5250720A (en) 1987-06-05 1993-10-05 The Dupont Merck Pharmaceutical Company Intermediates for preparing peptide boronic acid inhibitors of trypsin-like proteases
US5187157A (en) 1987-06-05 1993-02-16 Du Pont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
EP0315574A3 (de) 1987-11-05 1990-08-22 Hoechst Aktiengesellschaft Renin-Inhibitoren
WO1989009225A1 (en) 1988-03-28 1989-10-05 The Regents Of The University Of California Nerve growth factor peptides
US5023236A (en) 1988-04-07 1991-06-11 Corvas, Inc. Factor VII/VIIA active site inhibitors
US5106948A (en) 1988-05-27 1992-04-21 Mao Foundation For Medical Education And Research Cytotoxic boronic acid peptide analogs
US4963655A (en) 1988-05-27 1990-10-16 Mayo Foundation For Medical Education And Research Boron analogs of amino acid/peptide protease inhibitors
US5159060A (en) 1988-05-27 1992-10-27 Mayo Foundation For Medical Education And Research Cytotoxic boronic acid peptide analogs
DE3827340A1 (de) 1988-08-12 1990-02-15 Hoechst Ag Verwendung von (alpha)-aminoboronsaeure-derivaten zur prophylaxe und behandlung von viruserkrankungen
CA2077665A1 (en) 1990-03-05 1991-09-06 Robert Siman Chymotrypsin-like proteases and their inhibitors
ATE149563T1 (de) 1992-08-14 1997-03-15 Procter & Gamble Alpha-aminoborsäurehaltige flüssige waschmittel
WO1994009653A1 (en) 1992-11-02 1994-05-11 Quest International B.V. Tobacco material containing micro-organism cells
WO1994017816A1 (en) 1993-02-10 1994-08-18 The President And Fellows Of Harvard College Role of atp-ubiquitin-dependent proteolysis in mhc-1 restricted antigen presentation and inhibitors thereof
IL109319A0 (en) 1993-04-27 1994-07-31 Du Pont Merck Pharma Amidino and guanidino substituted boronic acid compounds
US5658885A (en) 1993-04-27 1997-08-19 The Dupont Merck Pharmaceutical Company Amidino and guanidino substituted boronic acid inhibitors of trypsin-like enzymes
JP3486412B2 (ja) 1993-04-30 2004-01-13 メルク エンド カンパニー インコーポレーテッド トロンビン阻害剤
US5672582A (en) 1993-04-30 1997-09-30 Merck & Co., Inc. Thrombin inhibitors
FR2707085B1 (fr) 1993-06-30 1995-08-18 Adir Nouveaux dérivés d'alpha amino acides, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
NZ274074A (en) 1993-10-01 1997-11-24 Merrell Pharma Inc Various dipeptide derivatives having a reduced carboxy group, the aldehyde being optionally substituted; pharmaceutical compositions
IL111175A0 (en) 1993-10-07 1994-12-29 Du Pont Merck Pharma Electrophilic peptide analogs as inhibitors of trypsin-like serine proteases and pharmaceutical compositions containing them
GB9401483D0 (en) 1994-01-26 1994-03-23 Sandoz Ltd Organic compounds
US5693617A (en) 1994-03-15 1997-12-02 Proscript, Inc. Inhibitors of the 26s proteolytic complex and the 20s proteasome contained therein
US6660268B1 (en) 1994-03-18 2003-12-09 The President And Fellows Of Harvard College Proteasome regulation of NF-KB activity
US6083903A (en) 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
US5614649A (en) 1994-11-14 1997-03-25 Cephalon, Inc. Multicatalytic protease inhibitors
US5550262A (en) 1994-11-14 1996-08-27 Cephalon, Inc. Multicatalytic protease inhibitors
US5834487A (en) 1996-09-24 1998-11-10 Cv Therapeutics Inhibition of 26S and 20S proteasome by indanones
UA79749C2 (en) 1996-10-18 2007-07-25 Vertex Pharma Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
GB9623908D0 (en) 1996-11-18 1997-01-08 Hoffmann La Roche Amino acid derivatives
US6096778A (en) 1997-10-07 2000-08-01 Cephalon, Inc. α-ketoamide multicatalytic protease inhibitors
CN1282242A (zh) * 1997-12-16 2001-01-31 赛福伦公司 多相催化蛋白酶抑制剂用作抗肿瘤剂
US6075150A (en) 1998-01-26 2000-06-13 Cv Therapeutics, Inc. α-ketoamide inhibitors of 20S proteasome
GB9806815D0 (en) 1998-03-30 1998-05-27 Hoffmann La Roche Amino acid derivatives
US6462019B1 (en) 1998-07-10 2002-10-08 Osteoscreen, Inc. Inhibitors of proteasomal activity and production for stimulating bone growth
EP0995757A3 (en) 1998-08-26 2002-05-22 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Bivalent inhibitors of the proteasome
CA2347275C (en) 1998-10-20 2010-03-09 Millennium Pharmaceuticals, Inc. Method for monitoring proteasome inhibitor drug action
CA2359561A1 (en) 1999-01-20 2000-07-27 Shiro Akinaga Proteasome inhibitors
EP1053750A1 (en) 1999-04-22 2000-11-22 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Use of proteasome-inhibitor for the induction of programmed cell death (apoptosis)
WO2000064863A1 (en) 1999-04-27 2000-11-02 Novartis Ag Use of 2,4-diamino-3-hydroxycarboxylic acid derivatives as proteasome inhibitors
SE9901573D0 (sv) 1999-05-03 1999-05-03 Astra Ab New compounds
EP1196436A2 (en) 1999-07-07 2002-04-17 Bristol-Myers Squibb Pharma Company Peptide boronic acid inhibitors of hepatitis c virus protease
US7122627B2 (en) 1999-07-26 2006-10-17 Bristol-Myers Squibb Company Lactam inhibitors of Hepatitis C virus NS3 protease
AU7832000A (en) 1999-09-23 2001-04-24 Washington University Compounds directed against pilus biogenesis and activity in pathogenic bacteria;methods and compositions for synthesis thereof
EP1221962A2 (en) 1999-10-20 2002-07-17 Osteoscreen, Inc. Inhibitors of proteasomal activity for stimulating bone and hair growth
WO2002008187A1 (en) 2000-07-21 2002-01-31 Schering Corporation Novel peptides as ns3-serine protease inhibitors of hepatitis c virus
JP2004510826A (ja) 2000-10-12 2004-04-08 ヴィローミクス　ゲゼルシャフト　ミット　ベシュレンクテル　ハフツング ウイルス感染の治療剤
EP2251344B2 (en) 2001-01-25 2024-04-24 THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Formulation of boronic acid compounds
IL158136A0 (en) 2001-04-09 2004-03-28 Method for identification of proteins from intracellular bacteria
US7214769B2 (en) 2001-05-23 2007-05-08 The Curators Of The University Of Missouri Method for inverse solid phase synthesis of peptides
WO2002096933A1 (en) 2001-05-30 2002-12-05 Novartis Ag 2-{[n-(2-amino-3-(heteroaryl or aryl)propionyl)-aminoacyl]-amino}-alkylboronic acid derivatives
WO2003015706A2 (en) 2001-08-16 2003-02-27 Washington State University Research Foundation Borinic acid protease inhibitors
JPWO2003033506A1 (ja) * 2001-10-12 2005-02-03 杏林製薬株式会社 アミノボラン酸誘導体およびそれを含有するプロテアソーム阻害薬
JPWO2003033507A1 (ja) 2001-10-12 2005-02-03 杏林製薬株式会社 ベンジルマロン酸誘導体およびそれを含有するプロテアソーム阻害薬
AU2003219652A1 (en) * 2002-01-08 2003-07-30 Eisai Co. Ltd. Eponemycin and epoxomicin analogs and uses thereof
US7223745B2 (en) * 2003-08-14 2007-05-29 Cephalon, Inc. Proteasome inhibitors and methods of using the same
US7442830B1 (en) * 2007-08-06 2008-10-28 Millenium Pharmaceuticals, Inc. Proteasome inhibitors
GEP20125599B (en) † 2007-08-06 2012-08-10 Millennium Pharm Inc Proteasome inhibitors

Also Published As

Publication number Publication date
ES2330008T3 (es) 2009-12-03
IL173722A0 (en) 2006-07-05
ES2330008T5 (es) 2017-06-28
US20090291918A1 (en) 2009-11-26
JP2007502304A (ja) 2007-02-08
US7915236B2 (en) 2011-03-29
HRP20090590T4 (hr) 2017-06-16
PL1660507T5 (pl) 2017-12-29
EP1660507B9 (en) 2010-03-24
AU2004268946B2 (en) 2012-01-19
HRP20090590T1 (hr) 2009-12-31
US20050107307A1 (en) 2005-05-19
US20120041196A1 (en) 2012-02-16
EP1660507A2 (en) 2006-05-31
WO2005021558A3 (en) 2005-05-12
DE602004022424D1 (de) 2009-09-17
NZ545775A (en) 2009-11-27
BRPI0413582A (pt) 2006-10-17
CA2535686A1 (en) 2005-03-10
EA200600414A1 (ru) 2006-08-25
EP1660507B1 (en) 2009-08-05
BRPI0413582B8 (pt) 2021-05-25
BRPI0413582B1 (pt) 2020-01-07
US20110144033A1 (en) 2011-06-16
PT1660507E (pt) 2009-10-15
US8058262B2 (en) 2011-11-15
IS8343A (is) 2006-03-08
MXPA06001687A (es) 2007-04-17
US9233115B2 (en) 2016-01-12
US8546608B2 (en) 2013-10-01
NO20150303L (no) 2006-05-11
HK1091839A1 (en) 2007-01-26
US7576206B2 (en) 2009-08-18
PL1660507T3 (pl) 2010-01-29
PH12012501372B1 (en) 2018-09-21
DK1660507T3 (da) 2009-11-02
IL173722A (en) 2012-06-28
EP1660507B2 (en) 2017-01-04
DK1660507T4 (en) 2017-03-27
IS3013B (is) 2019-05-15
SI1660507T1 (sl) 2010-01-29
US20140088042A1 (en) 2014-03-27
CY1109551T1 (el) 2014-08-13
IL217623A (en) 2015-06-30
EA010804B1 (ru) 2008-12-30
KR20060120585A (ko) 2006-11-27
PH12012501372A1 (en) 2013-09-02
JP4917431B2 (ja) 2012-04-18
CA2535686C (en) 2016-03-22
KR101093880B1 (ko) 2011-12-13
ATE438650T2 (de) 2009-08-15
CN102603781A (zh) 2012-07-25
AU2004268946A1 (en) 2005-03-10
WO2005021558A2 (en) 2005-03-10

Similar Documents

Publication Publication Date Title
NO20061197L (no) Proteasominhibitorer og fremgangsmater for anvendelse av samme
ATE423087T1 (de) Proteasome inhibitoren und deren verwendung
IL184678A0 (en) Proteasome inhibitors and methods of using the same
NO20083572L (no) Tiazolforbindelser som proteinkinase-B (PKB)-inhibitorer
NO20064976L (no) Azanidoler som er nyttige som inhibitorer av rock og andre proteinkinaser
NO20073140L (no) Pyrrolopyraziner og pyralopyraziner som er nyttige som inhibitorer av proteinkinaser
EA200870380A1 (ru) Аминотетрагидропираны в качестве ингибиторов дипептидилпептидазы-vi для лечения или предупреждения диабета
NO20091605L (no) Pyridinonforbindelser
NO20080150L (no) Inhibitorer av AKT-aktivitet
NO20064852L (no) Azaindoler som er nyttige som inhibitorer av jak og andre proteinkinaser
EA201000149A1 (ru) Производные 1-фенил-2-пиридинилалкиловых спиртов в качестве ингибиторов фосфодиэстераз
NO20061194L (no) Mitotiske kinesininbibitorer
NO20072567L (no) Triazoler nyttige som proteinkinase-inhibitorer
NO20080141L (no) Indanderivater som modulatorer av ionekanaler
EA201291099A1 (ru) Новые иммуномодуляторные и противовоспалительные соединения
EA200802223A1 (ru) 1,5-дифенилпиразолы ii в качестве ингибиторов hsp90
UA88771C2 (ru) Ингибиторы протеасомы и способ их применения (варианты)
ATE502935T1 (de) C-met-proteinkinasehemmer
EA200801008A1 (ru) Гипохолестеринемические соединения
DE60329326D1 (de) Tace inhibitoren

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application